NK‐ and T‐cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti‐CTLA‐4 therapy
出版年份 2019 全文链接
标题
NK‐ and T‐cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti‐CTLA‐4 therapy
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-04-25
DOI
10.1002/ijc.32363
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
- (2018) Kevin C. Barry et al. NATURE MEDICINE
- DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results.
- (2018) Anna K. Nowak et al. JOURNAL OF CLINICAL ONCOLOGY
- Tricking the balance: NK cells in anti-cancer immunity
- (2017) Jens Pahl et al. IMMUNOBIOLOGY
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
- (2017) Michele Maio et al. LANCET ONCOLOGY
- Estimation of the global burden of mesothelioma deaths from incomplete national mortality data
- (2017) Chimed-Ochir Odgerel et al. OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
- Natural killer cell-mediated immunosurveillance of human cancer
- (2017) Karl-Johan Malmberg et al. SEMINARS IN IMMUNOLOGY
- Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
- (2017) Elly Marcq et al. Oncotarget
- Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
- (2017) Yago Pico de Coana et al. Oncotarget
- IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients
- (2017) Rossana Tallerico et al. OncoImmunology
- Is There Room for Second-Line Treatment of Pleural Malignant Mesothelioma?
- (2017) Alfredo Addeo et al. JAMA Oncology
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
- (2016) Raphael Bueno et al. NATURE GENETICS
- Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) P. Baas et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- Investigation of serum proteome alterations in human endometriosis
- (2015) Mainak Dutta et al. Journal of Proteomics
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
- (2015) Emanuela Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer
- (2015) Christine Pasero et al. Oncotarget
- Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
- (2015) Luana Calabrò et al. Lancet Respiratory Medicine
- Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients
- (2015) Emanuela Taioli et al. PLoS One
- Immunomodulation in cancer
- (2014) Joost PJJ Hegmans et al. CURRENT OPINION IN PHARMACOLOGY
- Tim-3 on Peripheral CD4+ and CD8+ T Cells Is Involved in the Development of Glioma
- (2014) Song Han et al. DNA AND CELL BIOLOGY
- Tumor-released Galectin-3, a Soluble Inhibitory Ligand of Human NKp30, Plays an Important Role in Tumor Escape from NK Cell Attack
- (2014) Wei Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients
- (2014) Katarina M. Mirjačić Martinović et al. MELANOMA RESEARCH
- Tumor-Specific Cytotoxic T Cells Are Crucial for Efficacy of Immunomodulatory Antibodies in Patients with Lung Cancer
- (2013) J. G. Aerts et al. CANCER RESEARCH
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
- (2013) Luana Calabrò et al. LANCET ONCOLOGY
- Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer
- (2013) Jing Jiang et al. PLoS One
- Activating natural cytotoxicity receptors of natural killer cells in cancer and infection
- (2013) Joachim Koch et al. TRENDS IN IMMUNOLOGY
- Recognition and Prevention of Tumor Metastasis by the NK Receptor NKp46/NCR1
- (2012) A. Glasner et al. JOURNAL OF IMMUNOLOGY
- Immunotherapies for non-small-cell lung cancer and mesothelioma
- (2012) Anish Thomas et al. LANCET ONCOLOGY
- Optimal Thawing of Cryopreserved Peripheral Blood Mononuclear Cells for Use in High-Throughput Human Immune Monitoring Studies
- (2012) Hari Ramachandran et al. Cells
- Identification of Novel Markers for the Diagnosis of Malignant Pleural Mesothelioma
- (2011) Fabien Gueugnon et al. AMERICAN JOURNAL OF PATHOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells
- (2010) Sameena Khan et al. CLINICAL IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More